Published September 2, 2026
Every morning our data team scans the GLP-1 wire for stories that will actually matter to people who eat on these medications. This one — 'FDA approves Mounjaro to cut heart attack and stroke risk in high-risk type 2 diabetes', from Reuters via Devdiscourse (Aug 28, 2026) on 2026-09-02 — made the cut, and the analysis below connects it to the food data rather than repeating the press release.
This story is on our radar. We cover GLP-1 news by checking the source, then reading it through the same food lens we use everywhere: protein, fiber and fat. Where a story makes food claims, the USDA data is the referee.
What ties GLP-1 coverage together is a small set of food variables that keep resurfacing: protein protects the muscle you want to keep, fat is the strongest predictor of nausea on a slowed stomach, and fiber plus water manages constipation. This site's verdict system was built around those three because they are the ones that actually move outcomes.
Whatever the angle of the story — heart, kidney, muscle, side effects — the practical food response is remarkably consistent. That consistency is deliberate: the verdict labels are a fixed reference, so a reader does not need the news to know what to eat on any given day.
The honest limit: clinical stories are for clinicians. Food data answers 'what is in the food'; whether a headline applies to your dose, your body, or your treatment is a question for your healthcare provider. This post stays on the food side of that line, and says so out loud.
We cover a story when it is recent, sourced, and relevant to people who eat on a GLP-1. Unlinked rumors never make it to a page, because the site's whole method is traceability — applied to news the same way it is applied to food values.
The practical read of this story is simple: traceable sources and food data.
The plate does not change with the headline: protein anchors, vegetables fill, heavy food is portioned, water is constant.
Side-effect stories point to the two food levers — lower fat for nausea, more fiber plus water for constipation; outcome stories point to the same plate, day after day.
A headline is not a prescription: questions about your own dose or symptoms belong with your healthcare provider.
The site was designed around the week because the week is where the data stabilizes. Single meals wobble; the week tells the truth. The practical difference is small per meal, but a week of plates shows the actual pattern
of the plate: protein about a palm, vegetables to fill, the rich thing as a small side. It takes no measuring and survives busy weeks. The template survives because it is the shape the data keeps producing, and the values behind each slot are one link away
Before stopping a GLP-1, the food pattern and the dose are both worth reviewing with your clinician — most problems have a lever before the decision point. That division of labor is the cleanest way to keep a food site useful, while prescriptions and symptoms stay in the clinic
News about GLP-1 research rarely changes the food pattern: protein first, small portions, fiber and water. What a story can do is change which nutrient deserves attention — a muscle study points back to protein, a constipation survey points back to fiber — and the screen this site applies works the same way. If a headline affects your dose or treatment, that is a conversation with your clinician. The food data is a stable reference, not a news cycle.
No story should send you to a different plate by itself. The site's verdicts are built on USDA data and published frameworks, which change slowly and deliberately, not per news cycle. If a headline genuinely applies to you — your dose, your symptoms — that is a conversation for your clinician, not a menu rewrite.
Look for three things: a named source, a recent date, and a study or agency standing behind the claim. Journals like JAMA and NEJM and agencies like the FDA clear the bar; link-less headlines do not. Be skeptical of any story that overstates a single trial. This post names and links its source — the same standard we use for everything on the site.
Weekly is a good rhythm. The plate guidance shifts slowly, so there is no advantage to reading every headline the day it lands; the stable verdicts here cover the food side regardless. If a story does affect your treatment, the right next step is a conversation with your provider, not another article.
Source: Reuters via Devdiscourse (Aug 28, 2026) · 2026-09-02. We report the headline and its source, and we translate only the food-relevant context into this page.
From the data editorial team behind this site: every number above sits on a USDA-backed verdict page you can open. Thanks for stopping by — every claim above traces to the USDA values behind it
News coverage of GLP-1s moves fast, and our job is the slow part: connect the headline to the food data and ke
Eye doctors' consensus: GLP-1s may modestly raise rare…News coverage of GLP-1s moves fast, and our job is the slow part: connect the headline to the food data and ke
Tirzepatide can make the birth-control pill less reliable…Every morning our data team scans the GLP-1 wire for stories that will actually matter to people who eat on th